awmsg logo



sildenafil citrate (Revatio®)


Reference No. 1675

Publication date:
23/01/2013


Last review date:
30/09/2016

Appraisal information

sildenafil citrate (Revatio®) 10 mg/ml powder for oral suspension


Company: Pfizer Ltd
BNF category: Cardiovascular system
NMG meeting date: 07/11/2012
AWMSG meeting date: 12/12/2012
   
   
Submission Type: Limited Submission
Status: Recommended
Advice No: 4012
Ministerial ratification: 16/01/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Sildenafil (Revatio®) 10mg/ml powder for oral suspension is recommended as an option for use within NHS Wales for the treatment of paediatric patients aged 1 year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download